| Keisha Moore, | |
|
8048 N Celina St, Milwaukee, WI 53224-2904 | |
| (414) 750-8525 | |
| Not Available |
| Full Name | Keisha Moore |
|---|---|
| Gender | Female |
| Speciality | Licensed Vocational Nurse |
| Location | 8048 N Celina St, Milwaukee, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447704101 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164X00000X | Licensed Vocational Nurse | 312890-31 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Keisha Moore, 8048 N Celina St, Milwaukee, WI 53224-2904 Ph: (414) 750-8525 | Keisha Moore, 8048 N Celina St, Milwaukee, WI 53224-2904 Ph: (414) 750-8525 |
News Archive
New evidence-based educational guidelines evaluate the effectiveness of current continuing medical education (CME) practices and provide the first set of recommendations on how those practices need to change in the future.
Treating anemia with a class of drugs known as erythropoiesis-stimulating agents (ESAs) is associated with an increased risk of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs) and death among patients with cancer, according to an article in the February 27 issue of JAMA: The Journal of the American Medical Association.
Circadian Technologies Limited today released data demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth in a variety of different animal models (tumour xenografts) of human cancer.
Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.
People who see their relationships as either all good or all bad tend to have low self-esteem, according to a series of seven studies by Yale researchers published in the Journal of Personality and Social Psychology.
› Verified 9 days ago
Carese Lewis, LPN Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 4710 N 40th St, Milwaukee, WI 53209 Phone: 414-419-7652 | |
Tawana D Lynch, Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 2656 N Teutonia Ave Unit 6362, Milwaukee, WI 53206 Phone: 323-304-6447 | |
Landra Monique Brown, LPN Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 7608 W Waterford Ave, Milwaukee, WI 53220 Phone: 414-208-8139 | |
Ms. Khadijja Sabiah Ali, Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 6611 N Bourbon St, Milwaukee, WI 53224 Phone: 414-975-2376 | |
Hady Ndiaye, Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 3138 N 89th Street, Milwaukee, WI 53222 Phone: 414-873-2325 | |
Ms. Carol Andrews, LPN Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 3707 N Richards St, Milwaukee, WI 53212 Phone: 414-967-7006 Fax: 414-967-7020 |